tiprankstipranks
Trending News
More News >

Kissei’s YSELTY Gains European Approval for Endometriosis

Kissei’s YSELTY Gains European Approval for Endometriosis

Kissei Pharmaceutical Co (JP:4547) has released an update.

Confident Investing Starts Here:

Kissei Pharmaceutical Co. has announced that its GnRH antagonist YSELTY, developed for treating endometriosis, has been approved for this additional indication by the European Commission. This approval, which follows a positive opinion from the Committee for Medicinal Products for Human Use, allows YSELTY to expand its market presence in Europe. Despite this development, the company’s financial forecast for the fiscal year remains largely unchanged.

For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App